## Genetic variants associated with age-related traits and diseases in the Sardinian population.

David Schlessinger, Ph.D., NIH Distinguished investigator and Chief, Laboratory of Genetics, National Institute on Aging, NIH, USA, for collaborative efforts with the groups of Francesco Cucca, M.D./Ph.D., Director, Istituto di Ricerca Genetica e Biomedica, CNR, Italy, and Goncalo Abecasis, Professor of Statistical Genetics, U. of Michigan, Ann Arbor, USA.

Age-related diseases are "complex traits", influenced by many genes and environmental factors. Simplifying genetic studies, Sardinia provides a population that grew from an original cohort 10,000 years ago to a modern population of 1,500,000, and is relatively homogeneous but with excellent coverage of European genetic variation. Over 12 years the SardiNIA project has reported analyses in a group of 7,000 participants in a cluster of 4 towns, with comparable numbers of males and females aged 14 to 102, to find genetic factors affecting >300 quantitative traits. Participants repeat visits every 3 years to provide longitudinal information about diagnostic/prognostic value of findings. In >90 publications, genome-wide association studies have reported on anthropometric, blood chemistry, personality, pro-inflammatory molecules and cytokines, and recently, immune system cell traits (see Abstract of Francesco Cucca). Many of the genetic variants associated with traits are also risk factors for disease - for example, variants affecting both cholesterol and coronary artery disease. Based on sequencing of DNA and RNA of participants' lymphocytes, an enriched catalogue of non-coding RNA and coding gene variants provides further power to discriminate "causal" variants and mechanisms at loci identified by GWAS; analyses often reveal more than one associated variant in the same gene and thus account for an increasing fraction of heritability. In a direct assessment for a disease phenotype closely related to possible clinical intervention, variants in the transcription factor BCL11A were shown to prolong the formation of fetal hemoglobin - and thus alleviate thalassemia and sickle cell disease.